A Phase II Study of Single Tremelimumab With Regular Interval Durvalumab Plus Gemcitabine and Cisplatin in Locally Advanced Unresectable/Metastatic Combined Hepatocellular-cholangiocarcinoma
Hoosier Cancer Research Network
Hoosier Cancer Research Network
UMC Utrecht
Instituto do Cancer do Estado de São Paulo
Centre Oscar Lambret
University of California, Irvine
Dana-Farber Cancer Institute
Thomas Jefferson University
Stanford University
UNC Lineberger Comprehensive Cancer Center
Guangxi Medical University
Shanghai Zhongshan Hospital
Yonsei University
Case Comprehensive Cancer Center
University of Southern California
Thomas Jefferson University
National Cancer Centre, Singapore
Case Comprehensive Cancer Center
Kaohsiung Medical University Chung-Ho Memorial Hospital
University of Texas Southwestern Medical Center
The University of Texas Health Science Center at San Antonio
Fudan University
Thomas Jefferson University
Federation Francophone de Cancerologie Digestive
AHS Cancer Control Alberta
University of California, Irvine
University of Texas Southwestern Medical Center
Medical University of South Carolina
Shanghai Zhongshan Hospital
Asan Medical Center
Asan Medical Center
Georgetown University
Seoul National University Hospital
Memorial Sloan Kettering Cancer Center
University College, London
Beijing Tsinghua Chang Gung Hospital
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Shenzhen Third People's Hospital
Shenzhen Third People's Hospital
University of Chicago
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Second Affiliated Hospital of Guangzhou Medical University
Second Affiliated Hospital of Guangzhou Medical University
Sichuan Cancer Hospital and Research Institute
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
The University of Hong Kong
Beijing 302 Hospital
Zhongnan Hospital
The University of Hong Kong
Memorial Sloan Kettering Cancer Center
AIO-Studien-gGmbH